Alyeska Investment Group
PTCT icon

Alyeska Investment Group’s PTC Therapeutics PTCT Stock Holding History

Alyeska Investment Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-72,307
Closed -$5.49M – 721
2025
Q4 		$5.49M Buy
+72,307
New +$5.25M 0.02% 448
2025
Q3 		– Sell
-6,795
Closed -$332K – 694
2025
Q2 		$332K Buy
+6,795
New +$323K ﹤0.01% 529
2023
Q4 		– Sell
-360,000
Closed -$8.07M – 633
2023
Q3 		$8.07M Buy
360,000
+10,000
+3% +$372K 0.05% 307
2023
Q2 		$14.2M Buy
350,000
+200,000
+133% +$9.79M 0.11% 235
2023
Q1 		$7.27M Buy
+150,000
New +$6.86M 0.06% 275
2018
Q2 		– Sell
-30,000
Closed -$812K – 509
2018
Q1 		$812K Buy
+30,000
New +$760K 0.01% 400
2015
Q4 		– Sell
-24,158
Closed -$645K – 450
2015
Q3 		$645K Buy
+24,158
New +$1.03M 0.01% 411
2014
Q1 		– Sell
-119,440
Closed -$2.03M – 382
2013
Q4 		$2.03M Buy
119,440
+95,540
+400% +$1.68M 0.08% 228
2013
Q3 		$513K Sell
23,900
-111,100
-82% -$1.93M 0.02% 284
2013
Q2 		$2.02M Buy
+135,000
New +$2.19M 0.1% 198

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Alyeska Investment Group's PTCT Position: Q1 2026 in Review

Alyeska Investment Group sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 72,307 shares — an estimated $5.49M sold.

Alyeska Investment Group first reported a position in PTCT in Q2 2013 and held it in 10 quarters. The position peaked at $14.2M in Q2 2023. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Alyeska Investment Group reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 72,307 PTC Therapeutics shares in Q1 2026, an estimated $5.49M.
  • Alyeska Investment Group first reported a position in PTC Therapeutics in Q2 2013 and held it in 10 quarters.
  • Alyeska Investment Group's PTC Therapeutics position peaked at $14.2M in Q2 2023.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.